



# Amtagvi™ Cell Therapy Treatment Centers

## ETS Program Reference Guide

Emerging Therapy Solutions® (ETS) helps reinsurance and stop-loss payers, health plans, HMOs, and self-funded employers, along with third-party administrators and brokers, manage the risk associated with high-cost therapies for rare and complex conditions.

Programs listed here are qualified treatment centers (QTCs) for which ETS either may have contracted rates in place or may have access to rates through single case agreements for **Amtagvi** (Lifileucel) which is approved to treat **metastatic melanoma**.

For assistance with your member referral or for more information, contact ETS at 877-445-4822 or by email at [medicalservices@emergingtherapies.com](mailto:medicalservices@emergingtherapies.com).

▼ Denotes facilities that currently have cellular therapy rates in place with ETS.

State	City	Program Listing
Arizona	Scottsdale	Mayo Clinic
California	Duarte	City of Hope
	Stanford	Stanford Hospital and Clinics
	Los Angeles	U.C.L.A. Medical Center
	San Diego	U.C.S.D. Medical Center
	Los Angeles	University of Southern California- Keck Hospital of USC, USC Norris Cancer Hospital
Colorado	Denver	University of Colorado Hospitals
District of Columbia	Washington	Georgetown University Hospital
Florida	Tampa	H. Lee Moffitt Cancer Center ▼
	Jacksonville	Mayo Clinic
	Gainesville	UF Health Shands Hospital
	Miami	University of Miami Hospitals and Clinics
Georgia	Atlanta	Northside Hospital
Illinois	Chicago	Northwestern Memorial Hospital
Iowa	Iowa City	University of Iowa Hospitals
Kansas	Kansas City	University of Kansas Hospital
Maryland	Baltimore	University of Maryland Medical Center
Massachusetts	Boston	Dana-Farber Cancer Institute
		Massachusetts General Hospital
Minnesota	Rochester	Mayo Clinic
Missouri	St. Louis	Barnes-Jewish Hospital
Nebraska	Omaha	Nebraska Medical Center
New York	New York	Memorial Sloan-Kettering Cancer Center
	Buffalo	Roswell Park Cancer Institute

© 2024 Emerging Therapy Solutions, Inc. All Rights Reserved. AP-11235. ETS is a trademark of Emerging Therapy Solutions, Inc. All other trademarks referenced herein are the property of their respective owners. The information provided here is believed to be accurate as of the listed document production date and is based on information currently available to us. Because facility and program changes may occur, please confirm details with our ETS clinical consultants at 877-445-4822 or [medicalservices@emergingtherapies.com](mailto:medicalservices@emergingtherapies.com). Please note that coverage for any indicated services is subject to applicable plan documents. 11/27/2024



# Amtagvi™ Cell Therapy Treatment Centers

## ETS Program Reference Guide

▼ Denotes facilities that currently have cellular therapy rates in place with ETS.

State	City	Program Listing
North Carolina	Durham	Duke University Hospital
	Chapel Hill	University of North Carolina Hospitals
Ohio	Cleveland	Cleveland Clinic
	Columbus	James Cancer Hospital at Ohio State University
Oregon	Portland	Oregon Health & Science University ▼
Pennsylvania	Philadelphia	Thomas Jefferson University Hospital
Texas	Dallas	Baylor University Medical Center
	Houston	Houston Methodist Hospital
		M.D. Anderson Cancer Center
Utah	Salt Lake City	University of Utah Health Care
Washington	Seattle	Fred Hutchinson Cancer Center ▼
Wisconsin	Milwaukee	Froedtert and the Medical College of Wisconsin

© 2024 Emerging Therapy Solutions, Inc. All Rights Reserved. AP-11235. ETS is a trademark of Emerging Therapy Solutions, Inc. All other trademarks referenced herein are the property of their respective owners. The information provided here is believed to be accurate as of the listed document production date and is based on information currently available to us. Because facility and program changes may occur, please confirm details with our ETS clinical consultants at 877-445-4822 or [medicalsolutions@emergingtherapies.com](mailto:medicalsolutions@emergingtherapies.com). Please note that coverage for any indicated services is subject to applicable plan documents. 11/27/2024